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Cholinergic muscarinic receptors (MRs) and monoamine oxidase activity (MAO-B), expressed both in brain and blood cells,
were investigated in animals and exposed subjects to assess (i) MeHg (0.5–1mg/kg/day GD7-PD7) and/or PCB153 (20mg/kg/day
GD10–GD16) eﬀects on cerebellar MAO-B and MRs, and lymphocyte MRs, in dams and oﬀspring 21 days postpartum; (ii) MAO-
B in platelets and MRs in lymphocytes of a Faroese 7-year-old children cohort, prenatally exposed to MeHg/PCBs. Animal Data.
MAO-BwasalteredinmalecerebellumbyMeHg,PCB153,andtheircombination(35%,45%,and25%decrease,resp.).Cerebellar
MRs were enhanced by MeHg alone in dams (87%) and male pups (27%). PCB153 alone and in mixture did not modify cerebellar
MRs. Similarly to brain, lymphocyte MRs were enhanced in both dams and oﬀspring by MeHg alone. All changes were caused by
1MeHg mg/kg/day, the lower dose was ineﬀective. Human Data. Both biomarkers showed homogeneous distributions within the
cohort (MRs, range 0.1–36.78fmol/million cells; MAO-B, 0.95–14.95nmol/mg protein/h). No correlation was found between the
two biomarkers and neurotoxicant concentrations in blood (pre- and postnatally).
1.Introduction
In the last few decades, the continuous exposure of humans
to complex mixture of contaminating substances in food is
an issue that has been giving increasing cause for concern.
Clinical and experimental research has demonstrated the
high vulnerability of the developing nervous system to toxic
insults, leading to permanent alteration of brain functions
and pathologies later in life [1, 2]. Among the neurodevelop-
mental toxicants that received attention in this regard, meth-
ylmercury (MeHg) and polychlorinated biphenyls (PCBs)
represent a great public health concern, because low-level
chronic exposure can occur at various world sites through
the consumption of contaminated ﬁsh, seafood, and marine
mammals meat.
The neurotoxic hazard posed by MeHg and PCBs as well
as the unique susceptibility of the developing brain are well
documented [3, 4] but no deﬁnitive conclusion has yet been
reached about the dose-response relationship [5–7], that re-
main unclear, particularly in relation to concomitant expo-
sures.
Noteworthy, several epidemiologic studies on neurobe-
havioural endpoints in ﬁsh-eating populations at various
world sites, including the Faroe Islands [8], the Madeira Is-
land [9], the Brazilian Amazon basin, and more recent inves-
tigations on north-american Cree Indian infants, New-York-
ersandBostonianinhabitants,andEuropeanﬁshconsumers,
demonstratedmercury-relatedneuropsychologicalorneuro-
physiological adverse eﬀects in the oﬀspring, in the domains
of language, attention and memory, as well as visuospatial
and motor functions [6, 10, 11].
These eﬀects may have been augmented by concomitant
exposure to PCBs, which may aﬀect similar neurobehaviour-
al endpoints [12, 13].
Children exposed to PCBs and related chemicals in utero
or through breastfeeding have an increased incidence of
headaches, cognitive deﬁcits, and signiﬁcantly delayed psy-
chomotor development [14]. In experimental animal mod-
els, a number of long-lasting impairments, for example,
learning, behavioural, and neurochemical alterations have
been described following maternal exposure to PCBs [15–
19].2 Journal of Toxicology
Because human populations are often exposed to mix-
tures, as also for MeHg and PCBs in food, raising questions
about possible additive, synergistic, or antagonistic eﬀects of
the components [20], the potential of these pollutants to in-
teract, and the valuation of their joint eﬀects should be thor-
oughly investigated, even though it is extremely diﬃcult in
epidemiological studies.
To gain this goal, studies investigating biochemical pa-
rameters in easily accessible non-neural tissues, which are
similar to those targeted by chemicals in the brain (see [21]),
may represent a successful approach to developing markers
of neurotoxicity, which could be useful in exposed people
[22, 23]. In this respect, candidate non-invasive surrogate
markers include neurotransmitter receptors, enzymes, and
cell signalling components, which are measurable in blood,
plasma, lymphocytes, and/or platelets and can be aﬀected by
neurotoxicants in these peripheral tissues with changes mir-
roring those occurring in the brain [21, 24–27].
Examples of these peripheral markers include the cholin-
ergic muscarinic receptors (MRs) in lymphocytes and the
enzyme activity of monoamine oxidase-B (MAO-B) in plate-
lets [27–29].
The cholinergic system, essential for normal brain devel-
opment [30], is a sensitive target for MeHg neurotoxicity
[31, 32]. Both in vitro and in vivo evidences indicate that the
cholinergic muscarinic system can be aﬀected by MeHg
[25, 33–40], as well as by PCBs during development [41–43].
Notably, coexposure to MeHg and either PCB153 or PCB126
had the same eﬀe c to nt h ec e r e b r a lM R sa se x p o s u r et oe a c h
compound alone [28]. It has tobe considered that changes in
levels and activity of MRs have been implicated in the
pathophysiologyofmanymajordiseasesoftheCNS[44–48].
Noticeably, in mammalian species, most of the choliner-
gic components found in the CNS, including MRs, are also
expressed in non-neuronal tissues including lymphocytes
isolated from peripheral blood, thymus, lymph nodes, and
spleen [49]. Accordingly, some neurotransmission parame-
ters measured in rats, including lymphocytes MRs, after the
exposure to neurotoxicants and muscarinic drugs [35, 43,
50–52], have been shown to mirror equivalent changes of
these biochemical end-points in the CNS, thus providing
accessible measures of the same neurochemical endpoints
express in the CNS.
Both MeHg and PCBs may also aﬀect the central mono-
aminergic system as well. In fact, altered dopaminergic neu-
rotransmission has been observed following perinatal expo-
sure to MeHg (0.5mg/kg/day, GD7-PND7) in rats [53, 54];
moreover, MeHg can stimulate the spontaneous release
of monoamines from diﬀerent experimental CNS tissue
preparations [55, 56]. The most consistent neurochemical
eﬀects of noncoplanar PCBs have been found to be a reduc-
tion in dopamine (DA) concentrations besides an increase
in DA concentration both in cells and striatal tissue cultures
[57–59] as well as in laboratory animals brains after devel-
opmental or adult exposure (for a review, [18]), with an
exacerbation of the eﬀects of the two contaminants acting
synergistically when coadministrated [58]. On the other
hand, in a recent in vivo study, we demonstrated that
perinatal exposure to MeHg (0.5mg/kg/day) and/or PCB153
(5mg/kg/day) given orally to rat dams, aﬀected D1 and D2
receptorsinagender-,time-,andbrainarea-dependentfash-
ion, without additive eﬀects of the two chemical compounds
when administrated in mixture [60].
Noticeably, both MeHg and PCBs may alter the activity
of the enzyme monoamine oxidase (MAO), which play an
important role in the degradation of monoamine neuro-
transmitters as well as in the neurochemical regulation of
behaviour. Experimental evidences in laboratory animals
showed that (i) MeHg inhibited MAO activity both in vivo
and in vitro [61, 62] and (ii) prenatal exposure to PCB77
depressed postnatal development of MAO activity in whole
rat brain [63]. Recently, perinatal exposure to MeHg or
PCB153 in rats was shown to induce regional alterations of
the central dopaminergic and serotonergic systems at wean-
ing, but the combined treatment with both these toxicants
does not exacerbate the neurochemical eﬀects of the com-
pounds alone [28].
In humans, the MAO-B isoenzyme is the predominant
form in the brain and the sole type present in platelets. The
amino acid sequences of MAO-B in both platelets and brain
are identical [64], and the biochemical and pharmacological
characteristics of the enzyme are also similar in the two tis-
sues [65]. In this respect, platelet MAO has been widely used
as a model of central neuronal function and a surrogate
marker to investigate neurological and psychiatric disorders
[66–70].
With the ultimate goal to identify potential biomarkers
of CNS eﬀects, which can be applied as accessible tools to
use in environmental medicine for assessing and monitoring
speciﬁc exposure scenarios, a series of in vivo experimental
studies have been planned in our laboratory. Speciﬁcally, in
the attempt to advance knowledge on these biomarkers, a
ﬁrst-step study has been performed in order to evaluate (i)
brain and lymphocytes MRs and (ii) cerebral MAO-B activ-
ity, investigated in both dams and oﬀspring at weaning, after
perinatal exposure to MeHg (0.5mg/kg/day or 1mg/kg/day,
from gestational day (GD)7 to postnatal day (PD)7, and
PCBs (20mg/kg/day from GD10 to GD16) alone and in
combination. Then, in a second step, MRs in lymphocytes (l-
MRs)andMAO-Binplatelets(p-MAO-B)havebeenapplied
in a selected human population, with the aim at supporting




2.1. Animal Studies. All experimental procedures involving
animals were performed in compliance with the European
Council Directive 86/609/EEC on the care and use of lab-
oratory animals. Adult Sprague-Dawley rats (12 females and
4 males, 12 weeks old for each set of experiment) were
purchased from Charles River Italia (Calco, Italy) at least 2
weeks before mating and allowed to acclimatize for 3 weeks.
Throughout the experiment, animals were kept in an artiﬁ-
cial 12h light:12h dark cycle with humidity at 50 ± 10%.
Animals were provided rat chow (VRF1 diet) and tap water
ad libitum.Journal of Toxicology 3
To mimic human developmental dietary exposure to this
contaminant, rats were exposed to low-to-moderate doses of
MeHg and PCB153 in utero, through maternal oral con-
sumption.
The experimental regimen comprises 0.5 and 1mg
MeHg/kg (body weight) bw/day, administered to rat dams in
the drinking water from gestational day (GD)7 to postnatal
(PD)7, and/or PCB153 (20mg/kg/day) dissolved in corn oil,
administered to rats from GD10 to GD16.
The endpoints investigated in rats included total cholin-
ergic MRs and MAO-B activity in cerebellum and total MRs
in lymphocytes at weaning (i.e., PD21) both in dams and
their oﬀspring.
At the day of sacriﬁce, rat brains were rapidly dissected
on ice to isolate cerebellum from dams and oﬀspring and
stored at −80◦C until the analyses were performed. Spleens
were also collected.
2.2. Human Population. T h eF a r o e s eb i r t hc o h o r t( n = 182)
wasestablishedin1994–1995andconsistedofsingletonterm
births. The studies adhered to the Declaration of Helsinki
andhavebeenperformedafterapprovaloftheFaroeseethical
review committee. All subjects participating in the clinical
studies have been included after parental written informed
consent. Of the original 182 cohort members, 177 were eligi-
ble for participation in the 7-year examinations, and 166
agreed to participate (94%). A total of 159 children (76 boys,
83 girls) completed their examinations at 7 years of age with
a voluntary blood sample for the exposure analyses and for
the determination of biochemical markers: MAO-B activity
in platelet and MR binding in lymphocytes.
2.3. MR and MAO-B Determinations in Rat Cerebellum. (i)
Total MRs in cerebellum were determined by saturation
binding assays using the speciﬁc muscarinic antagonist
[3H]QNB, capable of labeling all subtypes of the MR family
uniformly[35,43,52].Bythesetechniques,thereceptorden-
sity (Bmax, expressed as femtomoles/mg protein) and aﬃn-
ity(deﬁnedasthereciprocalofthedissociationconstant,Kd)
were estimated by nonlinear regression analysis of saturation
binding data.
(ii) MAO-B activity was determined radiochemically as
described by Young et al., 1986 [71] using 10µM 14C-PEA as
the substrate. Speciﬁc MAO-B activity was determined in the
presence of 100µM pargyline hydrochloride. The reaction
was started by addition of 14C-PEA to 50µLo ft i s s u eh o m o -
genate (0.2mL ﬁnal volume) and stopped by addition of
0.1mL citric acid 2M after a 15-min incubation at 37◦C.
Deaminated reaction products were extracted into 3mL
toluene-ethylacetate (1:1, v/v) and the radioactivity con-
tained in a 1-mL aliquot of the organic phase was counted
in scintillation counter. The enzyme activity was expressed
as nmol/mg protein/h.
2.4.MRsDeterminationinLymphocytes. (i)Ratlymphocytes
were obtained from the spleen of controls and diﬀerently
treated animals [35]. MR density and aﬃnity in rat lympho-
cytes were determined as described in [52].
(ii) Human blood was collected in EDTA tubes and im-
mediately processed to isolate lymphocytes for MR binding
as previously described [72]. The lymphocytes were resus-
pended in the freezing solution [90% plasma obtained from
autologous blood kept on ice + 10% dimethylsulfoxide
(DMSO)]. Immediately after, the cells were gradually frozen
at −80◦C for 24h, and thereafter stored in liquid nitrogen.
Muscarinic receptors in humans were determined by
binding assays using a single concentration (Kd) of the spe-
ciﬁc tritiated ligand antagonist [3H]QNB for muscarinic
receptors in lymphocytes [72]. The speciﬁc binding was
measured in the presence or absence of atropine. Each sam-
ple was assayed in triplicate and data were expressed as
fmol/106 cells.
2.5. MAO-B Determination in Human Platelet. Human
blood was collected in EDTA tubes and immediately pro-
cessed to isolate platelets for MAO-B activity as previously
described [72]. The platelet-rich plasma (PRP) was diluted
with 10% DMSO, gradually frozen at −80◦C for 24h, and
thereafter stored in liquid nitrogen.
The activity of p-MAO-B was determined radiochemi-
cally in duplicate samples as described by Coccini et al., 2002
[66] using [14C-PEA] as the substrate. Speciﬁc activity was
determined in the presence of pargyline hydrochloride. The
enzyme activity was expressed as nmol/mg protein/h.
2.6. Analytical Measurements of Total Hg Levels in Rats.
MeasurementsoftotalHgincerebellumandbloodalsocom-
plemented the molecular studies to correlate neurochemical
changeswith theinternal doses (seemethods in [43, 52,73]).
2.7. Statistical Analysis. Data are presented as the mean ±
standard deviation. Data analysis was performed by one-way
analysis of variance (ANOVA) followed by Fisher’s posthoc
test using SPSS statistical software, considering probabilities
<0.05 as signiﬁcant. Statistical comparison of Hg concentra-
tions between groups (Hg versus Hg + PCB153) in brain
and blood of dams and both oﬀspring gender was performed
using Student’s t Test.
3. Results
The present study assessed (i) ﬁrstly, the individual and
joint eﬀect of MeHg (0.5 and 1mg/kg/day, GD7-PD7) and
PCB153 (20mg/kg/day, GD10–GD16), given orally to rat
dams, on the activity of cerebellar MAO-B and MRs as well
as on lymphocytes MRs, both in dams and oﬀspring 21 days
postpartum; and then (ii) MAO-B activity and MRs in 7-
year-old children from Faroese birth cohort, wherein pre-
natal exposure to MeHg and PCB had already been demon-
strated [29, 74].
3.1. Cerebellar MAO-B Activity. Figure 1(a) shows the eﬀects
of 1mg/kg/day MeHg (GD7-PND7) and/or 20mg/kg/day
PCB153 (GD10–GD16) maternal oral treatment on the cere-
bellar MAO-B activity at PD21 rats, evaluated both in dams






















































































(b1) Cerebellar MRs: Bmax values (b2) Lymphocytes MRs: Bmax values
(b)
Figure 1: Histograms showing cerebellar MAO-B activity (a) and MRs binding in cerebellum (b1) and lymphocytes (b2) of both dams and
21-day-old male and female rats, perinatally exposed to MeHg (1mg/kg/day, GD7-PND7) and PCB153 (20mg/kg/day, GD10–GD16), alone
or combined. Data are the mean ± SEM of n = 3–9 rats/treatment group/gender. ∗Signiﬁcantly diﬀerent from control group, P<0.05.
Thedoses,timingofMeHgandPCB153administrations,
and the time-point (PD21) to determine the neurochemical
endpoints were selected from previous experimental data
demonstratingchangesinratcerebralMRsdensity,following
the same regimen of perinatal exposure [42]. Furthermore,
this treatment protocol neither produced any noxious eﬀect
on pregnancy, litter size at birth and ratio between male
and female pups, maternal or neonatal body weight increase,
nor resulted in any gross abnormality to the pups (data not
shown).
In male rat cerebellum, in which the control levels of
MAO-B activity (nmol/mg protein/h) were 19.26 ± 2.05, all
diverse exposures caused signiﬁcant changes in the enzyme
activity (Figure 1(a)). Particularly, MeHg decreased MAO-
B activity by 35%, PCB153 by 45%, and the combined
treatment by 25%. On the contrary, in female pups, this neu-
rochemical endpoint was not aﬀected by any treatment
(Figure 1(a)), neither was in dams.
Noticeably, no eﬀects on MAO-B activity were observed
using the lower MeHg dose (0.5mg/kg/day from GD7 to
PND7) in both male and female oﬀspring (data not present-
ed).
The radiochemical method, employed in the present
study to determine MAO-B activity, did not allow the detec-
tion of this enzyme in rat platelets.
3.2. Cerebellar MRs Density (Bmax). In accordance to previ-
ous investigations [75], all determinations were done at the
end of the lactational period (PND21), a time at which the
total MR binding sites reach adult levels in rats.
Exposure to the higher dose of MeHg (1mg/kg/day) sig-
niﬁcantly enhanced cerebellar MRs density in dams (87%),
and, in the oﬀspring, Bmax increase was observed in the
male pups only (27%) (Figure 1(b1)). Diﬀerently from the
response to MeHg, PCB153 did not modify cerebellar MRs
density both in adult and oﬀspring. After the concomitantJournal of Toxicology 5
Table 1: Total Hg levels in blood and brain of rats perinatally treated with 1mg MeHg/kg bw/day (GD7-PD7) and/or 20mg
PCB153/kgbw/day (GD10–GD16), alone and in combination.
Blood Hg (µg/ml) Brain Hg (µg/g)
Dams Oﬀspring Dams Oﬀspring


































Data are the mean ± S.D.
exposuretoMeHg(1mg/kg/day)andPCB153,theMRsden-
sity was similar to that detected after the administration of
PCB153 alone(Figure 1(b1)).
Noticeably, the lower dose of MeHg (0.5mg/kg/day)
either alone or in combination with PCB153 did not cause
any change in MR density both in the mother and oﬀspring
cerebella (data not shown).
C e r e b e l l a rc o n t r o lK dv a l u e sw e r e0 .085 ± 0.02, 0.078 ±
0.01, 0.080 ± 0.01nM in dams, male, and female oﬀspring,
respectively. MeHg and PCB153, alone and in combination,
didnotaﬀectthedissociationconstantvalues(Kd)measured
both in dams and oﬀspring, thus suggesting that the aﬃnity
of the ligand [3H]QNB for its receptor was not modiﬁed by
these compounds.
3.3. Lymphocytes MRs: Animal Data. Exposure to 1mg
MeHg/kg/day during pregnancy and lactation (from GD7 to
PND7) signiﬁcantly enhanced lymphocyte MR density in
both dams and 21 day-old rats, with a more pronounced
eﬀect in the mothers (Bmax increase of 139%) than in
the male oﬀspring (+49%) and female oﬀspring (+73%) as
compared with their respective controls (33 ± 4, 41 ± 8,
and 37 ± 4fmol/million cells, Figure 1(b2)), in accordance
with the higher Hg levels detected in the adult blood (11.3 ±
2.26mg/mL) than in pups (1.35 ± 0.4mg/Linbothgenders,
Table 1), and in absence of any change in their Kd values
(control Kd values were 30 ±10nM).
Again,whenthelowerdoseofMeHg(0.5mg/kg/day)was
administered to dams, the density of MRs of all groups did
not signiﬁcantly diﬀer from that of their control groups on
day 21 postpartum. This dose of MeHg was also devoid of
any eﬀect on the Kd values (data not shown).
3.4. Brain and Blood Hg Levels in Rats. Hg levels were
measured in whole brains and blood of both dams and 21-
day-old pups (separate accordingly to gender) treated with
1mg MeHg/kg/day. The Hg concentrations (Table 1) in the
brain were about ﬁve-fold higher in the mother than in the
oﬀspring and resulted to be not aﬀected by the coexposure to
PCB153.
Regarding the Hg retention in blood, the levels in the
dams were about 10-fold higher than those found in both
male and female oﬀspring (Table 1).
3.5. Neurochemical Markers in Humans: Lymphocytes MRs
and p-MAO-B. The levels of the lymphocytes MR binding
(n = 139) and p-MAO-B activity (n = 137) measured in
the blood of both female and male Faroese children are
shown in the Figures 2(a) and 2(b). Figure 2(b) shows the
single values of the MR binding in boys (n = 73) and girls
(n = 66), respectively. The MR binding was similar in boys
and girls and ranged from 0.1 to 36.78fmol/million cells
in boys and from 0.1 to 35.91 fmol/million cells in girls.
Figure 2(a) illustrates the individual values of the MAO-B
activity in both male (n = 70) and female (n = 67) children,
respectively. Even for this neurochemical endpoint, the data
were similar in both genders (ranges: 0.95–14.57 and 1.57–
14.95nmol/mg protein/hr for boys and girls, resp.).
No correlation (by regression analysis) was found be-
tween the two neurochemical biomarkers and neurotoxicant
concentrations in blood (pre- and postnatally) [29].
4. Discussion
The present study demonstrates in laboratory animals
that developmental exposure to MeHg (1mg/kg/day, GD7-
PND7) and PCB153 (20mg/kg/day, GD10–GD16), alone
and in mixture, aﬀects selected endpoints of cholinergic and
monoaminergic transmission, namely, cerebellar MAO-B
activity and cerebellar and lymphocyte MRs, both in dams
and weaning rats, 3 weeks after cessation of maternal dosing.
In the CNS, MAO-B activity was signiﬁcantly decreased
(25–45%) by all treatment types in the cerebellum of male
pupsonly.ThecombinedexposuretoMeHgandPCB153did
not exacerbate the neurochemical eﬀects of the individual
compounds.
MRs density was signiﬁcantly aﬀected by MeHg alone
both in dams and male oﬀspring cerebella (Bmax enhance-
ment of 87% and 27%, resp.), while, in the coexposed group,
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Figure 2: Levels of (a) p-MAO-B activity (n = 137) and (b) l-MR binding measured in the blood of both female and male Faroese children.
(a) illustrates the individual values of the MAO-B activity in 70 boys (mean ± SD = 6.08 ± 3.12nmol/mg protein/h, range: 0.95–14.57) and
67 girls (mean ± SD = 5.56 ± 2.55nmol/mg protein/h, range: 1.57–14.95), respectively. (b) shows the single values of the MR binding in 73
boys (mean ± SD = 8.05 ± 9.13 fmol/106 cells, range: 0.1–36.78) and 66 girls (mean ± SD = 8.09 ± 8.31 fmol/106 cells, range: 0.1–35.91),
respectively.
MRs measured in peripheral lymphocytes also displayed
alterations similar to those occurring in the cerebellum, in
that MeHg alone signiﬁcantly enhanced MRs density both in
dams and oﬀspring, (Bmax increase of 139%, 49%, and 73%
for dams, males, and females, resp.), and, when in combina-
tion with PCB153, the latter compound masked the MeHg
eﬀects.
In another set of experiments, testing the lower MeHg
dose (0.5mg/kg/day, GD7-PND21), no eﬀects were detected
forallthechosencholinergicandmonoaminergicendpoints.
Altogether the present results, obtained both in neural
tissue and in peripheral cells, are in agreement with a large
body of previous experimental evidence strongly supporting
thenotionthatMRbindingismodulatedinasimilarmanner
in lymphocytes and cerebral tissues. Supporting examples of
this parallel modulation come from cholinergic agonist and
antagonist drugs [50]a sw e l la sb ye n v i r o n m e n t a lc h e m i c a l s ,
such as MeHg [35] and organophosphorous insecticides
[51]. Moreover, the MRs were shown to be similarly mod-
ulated in rat brain and in lymphocytes following repeated
perinatal MeHg exposure [52].
Again, the present investigation demonstrates that the
eﬀects measured in lymphocytes MRs of animals coexposed
to MeHg and PCB153 mirror the changes observed in cere-
bellum, in which the chemical mixture produced no detect-
able MR alterations.
Based on (i) the results obtained from this laboratory
animal study (above reported), (ii) the need to identify early
biomarkers of eﬀects for delay neurological outcomes due
to environmental neurotoxicants exposure, and (iii) the op-
portunity to measure these biochemical parameters in easily
accessible non-neural tissues, we are prompted to evaluate
these peripheral surrogate markers in a speciﬁc human ca-
sistic.
The human study, performed in a cohort of 7-year-old
children with widely diﬀerent degrees of MeHg exposure,
with a built-in control group with low-level exposure, indi-
cates that children exhibited homogeneous distributions of
the two neurotoxicity biomarkers with no changes associated
with increased concentrations of mercury or coexposure
with PCB congeners and with no clear association with out-
comes of clinical neurobehavioral testing.
These results seem to support the notion that p-MAO-
B and l-MRs are not adequately sensitive markers to early
detectthesubclinicaloutcomesofMeHgand/orPCBsatlow/
moderate exposure doses.Journal of Toxicology 7
Contrarily, recent investigation by Stamler et al. 2006
[68] in a Canadian ﬁsh-eating population inhabiting the St.
Lawrence River (Lake St. Pierre, Quebec) demonstrated a
MeHg-inducedreductioninMAO-Bactivity,associatedwith
blood-Hg concentrations above 3.4µg/L.
On the other hand, in animal studies, the used perinatal
dose of 1mg MeHg/kg/day markedly aﬀected the rat cholin-
ergicandaminergicsystems,while,contrarily,thelowerdose
of 0.5mg MeHg/kg/day was totally ineﬀective. After the
former treatment, cerebral Hg levels in weaning rats were
1.5–2.8ppm and blood Hg levels were 1.3 ±0.4µg/mL (in
both pup genders). These latter data are clearly much higher
(250 to 40 times) compared to humans blood Hg levels, for
instance, 1300ppb (in rat blood at PD21) versus 27.6 and
5.27ppb in cord blood and 7-year-old children blood of the
present cohort, respectively [29]. These observations put for-
ward that MeHg-exposure levels may aﬀect the alterations in
neurotransmission pathways and, consequently, the changes
in both central and peripheral markers. Furthermore, other
confounding factors, such as genetic variables, may also be
to taken into consideration for their potential impact on the
background levels of these biomarkers [76–79].
Moreover, since the precise time point at which these
peripheral biomarkers become predictive of neuropsycho-
logical outcomes (noticeable later in life) has not been yet
clariﬁed, this should be investigated correlating these param-
eters (neurochemical and neuropsychological) in an early
(e.g., cord blood) and late time point manner within the
same subject. In this way, one could try to minimize the
inﬂuenceofthebloodcellturnoveronthelevelsofthesecell-
coupled surrogate markers, in that, because of this mech-
anism, the response to a moderate environmental toxicant
exposuremaynotreﬂectthepossibleeﬀectatvulnerabletime
windows (e.g., in utero period) that may cause permanent
changes in neuropsychological outcomes.
Nevertheless, a great body of epidemiological evidence
indicated the suitability of these biomarkers when employed
as peripheral indicators of abnormal behaviour/personality
or changes in response to a diagnosed pathological condi-
tions [80–82], and drug dependence [66, 83–85].
Therefore, even though all these above-reported ﬁndings
and the available bulk of literature seem to be sometimes and
somewhere controversial, integrated approaches combining
biochemical markers in combination with neurophysiolog-
ical and behavioral assays could represent a valuable meth-
odological approach by which human neurotoxicity assess-
ment may become more focused.
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